{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:52:16Z","timestamp":1789404736046,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA009566"],"award-info":[{"award-number":["T32CA009566"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008169","name":"Minneapolis Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clml.2022.07.002","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T02:26:42Z","timestamp":1657506402000},"page":"e1000-e1008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-1335","authenticated-orcid":false,"given":"Ajay","family":"Major","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.07.002_bib0001","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.002_bib0002","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.002_bib0003","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/BLCTT.S91251","article-title":"Managing treatment-related peripheral neuropathy in patients with multiple myeloma","volume":"6","author":"Petrucci","year":"2016","journal-title":"Blood Lymphat Cancer Targets Ther"},{"key":"10.1016\/j.clml.2022.07.002_bib0004","first-page":"2411","article-title":"Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice","volume":"24","author":"Beijers","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2022.07.002_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.637593","article-title":"Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study","volume":"12","author":"Selvy","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clml.2022.07.002_bib0006","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.07.002_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.07.002_bib0008","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.002_bib0009","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.002_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.008","article-title":"Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: a systematic review","volume":"125","author":"Mushtaq","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2022.07.002_bib0011","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.clml.2022.07.002_bib0012","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.002_bib0013","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2022.07.002_bib0014","first-page":"37","volume":"136","author":"Tan","year":"2020","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2022.07.002_bib0015","doi-asserted-by":"crossref","first-page":"e19531","DOI":"10.1200\/jco.2015.33.15_suppl.e19531","article-title":"Real world impact of treatment-induced peripheral neuropathy (TIPN) on patient reported outcomes (PROs) in patients with multiple myeloma (MM) in the United States","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.002_bib0016","doi-asserted-by":"crossref","first-page":"S715","DOI":"10.1016\/j.jval.2020.08.1879","article-title":"PRO143 Costs of multiple myeloma patients diagnosed with peripheral neuropathy in Germany","volume":"23","author":"Lebioda","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2022.07.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719839025","article-title":"Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis","volume":"10","author":"Song","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2022.07.002_bib0018","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.bbmt.2018.03.027","article-title":"Health-related quality of life after autologous stem cell transplantation for multiple myeloma","volume":"24","author":"Chakraborty","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2022.07.002_bib0019","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/10428194.2020.1719091","article-title":"Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"61","author":"Roussel","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.07.002_bib0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0609.2009.01404.x","article-title":"What changes in health-related quality of life matter to multiple myeloma patients? A prospective study","volume":"84","author":"Kvam","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.07.002_bib0021","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.002_bib0022","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.002_bib0023","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.002_bib0024","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.002_bib0025","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.002_bib0026","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.002_bib0027","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.002_bib0028","first-page":"2959","article-title":"Impact of oxaliplatin-induced neuropathy: a patient perspective","volume":"20","author":"Bennett","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2022.07.002_bib0029","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/annonc\/mdp287","article-title":"Clinician versus nurse symptom reporting using the National Cancer Institute\u2014Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire","volume":"20","author":"Cirillo","year":"2009","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2022.07.002_bib0030","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2018-99-113087","article-title":"Patient treatment preferences for relapsed\/refractory multiple myeloma: are patients willing to trade off efficacy for tolerability?","volume":"132","author":"Auclair","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.002_bib0031","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/17474086.2020.1729734","article-title":"Real-world outcomes and factors impacting treatment choice in relapsed and\/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd","volume":"13","author":"Chari","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2022.07.002_bib0032","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","author":"Costa","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:53Z","timestamp":1761871253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2152265022002191"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}